Indication

Recurrent Olfactory Neuroblastoma

1 clinical trial

1 product

Clinical trial

A Phase II Study of Rivoceranib for Patients With Recurrent or Metastatic Olfactory Neuroblastoma

Status: Not yet recruiting, Estimated PCD: 2026-11-30

Product